SOURCE: Cell Signaling Technology

December 17, 2007 12:04 ET

For the First Time, Cancer Research by Cell Signaling Technology Comprehensively Examines Cell Circuitry That Drives Malignancy

DANVERS, MA--(Marketwire - December 17, 2007) - In a significant breakthrough, Cell Signaling Technology (CST) ( is publishing several papers describing how researchers look inside cancer cells at the complex cell circuitry that drives malignancies.

According to Michael Comb, Ph.D., President and CEO of Cell Signaling Technology, "CST's new technology opens a new view of what goes wrong in cancer cells, as well as other diseases such as diabetes and neurodegenerative disorders."

Two new papers in the December and January 2007 issues of the Proceedings of the National Academy of Sciences (PNAS) describe the application of CST's proprietary PhosphoScan® technology to discover new causes of cancer and mechanisms of drug action, advancing the understanding of cellular defects that drive a cell to become malignant.

A report published in Cell, December 2007 ( describes the application of this approach to solid tumors such as lung cancer and demonstrates how the technology can identify new sub-types of lung cancer. The study also points the way to new therapies that will likely save many lives in the future.

"CST's new technology can now be applied broadly across many different types of cancer," continued Dr. Comb. "Previously, scientists have been able to study large-scale changes in gene expression and chromosomal abnormalities to great advantage, but until now have been unable to look at a similar scale inside the cell at the circuits that drive a cell to become malignant."

Dr. Comb added, "The paper published in Cell shows, for the first time, how the activity of many different signaling pathways -- or cell circuitry in cancer cells -- can be surveyed and measured to locate pathways and molecules that cause and drive cancer. Up until now, molecules and pathways have been studied one at a time, making it impossible to examine the large number of different signaling pathways involved in cancer."

The ability to identify pathways defective in disease has resulted in targeted therapies designed to block cancer-causing signals and return the cell to normal. These targeted therapies have proven highly successful, but work only in a subset of patients, those patients whose tumors are driven by the activated pathway the drug targets. Hence, it becomes essential to match a drug with pathway activity in order to effectively treat patients with a personalized or targeted medicine.

"Research findings published this month from CST are an important step towards developing the technologies and diagnostic assays needed to identify the molecular cause(s) of cancer. This information will, in the future, help physicians prescribe the most effective cancer drugs and therapies," concluded Dr. Comb.

About Cell Signaling Technology

Cell Signaling Technology, Inc. is a worldwide leader in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis, as well as novel discovery technologies such as PhosphoScan®. PhosphoScan® leverages CST's core capabilities in antibody development to deliver insight into cellular phosphorylation and acetylation profiles enabling more efficient and informative kinase drug discovery and clinical development. Information on CST can be obtained at the Company's website at

Contact Information

  • For further information contact:
    Eric Scharf
    Cell Signaling Technology
    Email Contact
    Steven Swartz
    Email Contact